Zacks
IDEXX Laboratories Stock Climbs 39.4% in a Year: What's Driving It?
📈
AI Sentiment
Highly Positive
8/10
- Home
- IDXX
as of 03-10-2026 3:39pm EST
$602.19
$9.26
-1.51%
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
| Founded: | 1983 | Country: | United States |
| Employees: | N/A | City: | WESTBROOK |
| Market Cap: | 57.1B | IPO Year: | 1996 |
| Target Price: | $715.00 | AVG Volume (30 days): | 437.8K |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 13.08 | EPS Growth: | 22.59 |
| 52 Week Low/High: | $356.25 - $769.98 | Next Earning Date: | 05-04-2026 |
| Revenue: | $4,303,702,000 | Revenue Growth: | 10.42% |
| Revenue Growth (this year): | 10.83% | Revenue Growth (next year): | 8.60% |
| P/E Ratio: | 46.46 | Index: | |
| Free Cash Flow: | 1.1B | FCF Growth: | +30.82% |
Stock Insider Trading Activity of IDEXX Laboratories Inc. (IDXX)
Hunt Nimrata
Sell
Executive Vice President
IDXX Mar 3, 2026
Avg Cost/Share
$634.57
Shares
1,758
Total Value
$1,115,577.22
Owned After
18,140.944
SEC Form 4
MAZELSKY JONATHAN JAY
Sell
President and CEO
IDXX Feb 26, 2026
Avg Cost/Share
$656.80
Shares
23,326
Total Value
$15,338,080.78
Owned After
86,195.302
Hunt Nimrata
Sell
Executive Vice President
IDXX Feb 26, 2026
Avg Cost/Share
$661.54
Shares
2,693
Total Value
$1,781,530.72
Owned After
18,140.944
SEC Form 4
Vandebroek Sophie V.
Sell
Director
IDXX Feb 17, 2026
Avg Cost/Share
$628.60
Shares
1,464
Total Value
$920,293.11
Owned After
648
Erickson Michael G
Sell
Executive Vice President
IDXX Feb 17, 2026
Avg Cost/Share
$627.07
Shares
5,371
Total Value
$3,369,666.17
Owned After
12,733.351
FENNELL GEORGE
Sell
Executive Vice President
IDXX Feb 10, 2026
Avg Cost/Share
$646.76
Shares
11,345
Total Value
$7,336,993.27
Owned After
20,038
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Hunt Nimrata | IDXX | Executive Vice President | Mar 3, 2026 | Sell | $634.57 | 1,758 | $1,115,577.22 | 18,140.944 | |
| MAZELSKY JONATHAN JAY | IDXX | President and CEO | Feb 26, 2026 | Sell | $656.80 | 23,326 | $15,338,080.78 | 86,195.302 | |
| Hunt Nimrata | IDXX | Executive Vice President | Feb 26, 2026 | Sell | $661.54 | 2,693 | $1,781,530.72 | 18,140.944 | |
| Vandebroek Sophie V. | IDXX | Director | Feb 17, 2026 | Sell | $628.60 | 1,464 | $920,293.11 | 648 | |
| Erickson Michael G | IDXX | Executive Vice President | Feb 17, 2026 | Sell | $627.07 | 5,371 | $3,369,666.17 | 12,733.351 | |
| FENNELL GEORGE | IDXX | Executive Vice President | Feb 10, 2026 | Sell | $646.76 | 11,345 | $7,336,993.27 | 20,038 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 2, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYFeb 2, 2026 · 100% conf.
AI Prediction BUY
1D
+1.19%
$647.19
Act: -1.10%
5D
+5.23%
$673.07
Act: +0.03%
20D
+4.79%
$670.23
Act: -0.63%
Price: $639.60 Prob +5D: 100% AUC: 1.000
0001104659-26-008904
false
IDEXX LABORATORIES INC /DE
0000874716
0000874716
2026-02-02 2026-02-02
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): February 2, 2026
IDEXX
LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
Delaware
000-19271
01-0393723
(State or other jurisdiction
(Commission File Number)
(IRS
Employer Identification No.)
of incorporation)
One IDEXX Drive, Westbrook, Maine 04092
(Address of principal executive offices)
(ZIP
Code)
207.556.0300
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.10 par value per share
IDXX
NASDAQ
Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02Results of Operations and Financial Condition.
On February 2, 2026, IDEXX Laboratories, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
In accordance with general instructions to Form 8-K, the information in this Form 8-K and the Exhibit 99.1 attached hereto is being furnished under Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits
The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed.
Exhibit No. Description of Exhibit
99.1Press Release entitled “IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results,” issued by the Company on February 2, 2026.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IDEXX LABORATORIES, INC.
Date: February 2, 2026 By: /s/ Andrew Emerson
Andrew Emerson
Executive Vice President,
Chief Financial Officer and Treasurer
2
2025 Q3 Q3 2025 Earnings
8-K Nov 3, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 3, 2025
0001104659-25-105185
false
IDEXX LABORATORIES INC /DE
0000874716
0000874716
2025-11-03 2025-11-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 3, 2025
IDEXX
LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
Delaware
000-19271
01-0393723
(State or other jurisdiction
(Commission File Number)
(IRS
Employer Identification No.)
of incorporation)
One IDEXX Drive, Westbrook, Maine
04092
(Address of principal executive offices)
(ZIP
Code)
207.556.0300
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.10 par value per share
IDXX
NASDAQ
Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02Results of Operations and Financial Condition.
On November 3, 2025, IDEXX Laboratories, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
In accordance with general instructions to Form 8-K, the information in this Form 8-K and the Exhibit 99.1 attached hereto is being furnished under Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits
The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed.
Exhibit No.Description of Exhibit
99.1Press Release entitled “IDEXX Laboratories Announces Third Quarter Results,” issued by the Company on November 3, 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IDEXX LABORATORIES, INC.
Date: November 3, 2025 By: /s/ Andrew Emerson
Andrew Emerson
Executive Vice President,
Chief Financial Officer and Treasurer
3
2025 Q2 Q2 2025 Earnings
8-K Aug 4, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 4, 2025
0001104659-25-073304
false
IDEXX LABORATORIES INC /DE
0000874716
0000874716
2025-08-04 2025-08-04
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 4, 2025
IDEXX
LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
Delaware
000-19271
01-0393723
(State or other jurisdiction
(Commission File Number)
(IRS
Employer Identification No.)
of incorporation)
One IDEXX Drive, Westbrook, Maine
04092
(Address of principal executive offices)
(ZIP
Code)
207.556.0300
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.10 par value per share
IDXX
NASDAQ
Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02Results of Operations and Financial Condition.
On August 4, 2025, IDEXX Laboratories, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
In accordance with general instructions to Form 8-K, the information in this Form 8-K and the Exhibit 99.1 attached hereto is being furnished under Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01Financial Statements and Exhibits.
(d)Exhibits
The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed.
Exhibit No. Description of Exhibit
99.1Press Release entitled “IDEXX Laboratories Announces Second Quarter Results,” issued by the Company on August 4, 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IDEXX LABORATORIES, INC.
Date: August 4, 2025 By: /s/ Andrew Emerson
Andrew Emerson
Executive Vice President, Chief Financial Officer and Treasurer
2
Latest IDEXX Laboratories Inc. News
IDXX Breaking Stock News: Dive into IDXX Ticker-Specific Updates for Smart Investing
Zacks
SONVY vs. IDXX: Which Stock Should Value Investors Buy Now?
📈
AI Sentiment
Highly Positive
8/10
Compare IDXX vs Leading Stocks
See how IDXX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IDXX IDEXX Laboratories Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.